Jefferies reiterates Sarepta stock rating on regulatory pathway

Jefferies reiterated a Buy and $30.00 price target on Sarepta (SRPT) and the company plans to submit two supplemental NDAs by end‑April to convert accelerated approvals for AMONDYS 45 and VYONDYS 53 to traditional approvals, with FDA decisions expected by Feb 2027; Jefferies estimates the conversion could move the stock 15–25%. Shares trade at $16.79 (down ~79% over the past year) despite combined 2025 sales of $425M for AMONDYS/VYONDYS and Jefferies modeling Elevidys potential >$500M annually; InvestingPro analysts expect EPS of $4.06 for the year. Mizuho raised its price target to $31 (Outperform) while Cantor Fitzgerald stayed Neutral but cut 2026 revenue estimates, and Sarepta has begun a sirolimus safety trial for ELEVIDYS to mitigate AAV-related liver injury ahead of upcoming Phase I/II siRNA data expected in 1H–2H 2026.

Analysis

The market is pricing this company as a high-volatility, binary biotech where de-risking events meaningfully compress the discount rate and reduce implied required returns. If upcoming regulatory and clinical datapoints are viewed as directional rather than binary, expect volatility to fall and relative multiples to expand — a 12–24 month window is realistic for a re-rating if adoption and label durability track clinical expectations.

Second-order winners are the manufacturing and supply-chain providers for advanced modalities: capacity reallocation or ramp needs will shift margins toward specialized CDMOs and away from commoditized oligo producers, creating transient pricing power. Conversely, concentrated manufacturing creates single-point failure risk; any production hiccup would cascade into revenue misses and extended timelines for both core and follow-on programs.

Key risks are classic for this space: an adverse safety signal or aggressive payer restrictions can reverse sentiment quickly, and these are identifiable weeks to months ahead of full commercial inflection. The consensus is somewhat optimistic on uptake and underestimates payer negotiation timelines; that makes measured, event-driven exposure attractive rather than full-blown conviction positions.

Key Decisions for Investors

• Long asymmetric options (ticker: SRPT) — Buy 12–18 month LEAP calls sized to 1–1.5% of fund NAV (e.g., Jan-2027 expiries) with a 2x target on option premium and a hard stop at -50% premium. Rationale: captures re-rating if volatility compresses post de-risking while limiting cash at risk to a defined premium.
• Equity with downside protection (ticker: SRPT) — Initiate a 1.5–2.5% NAV long equity position and buy protective puts to cap downside at ~20% for a 9–12 month horizon; sell a covered call at ~50% upside to fund protection if comfortable limiting upside. R/R: asymmetric upside (target +40–60%) with controlled downside.
• Pair trade to isolate idiosyncratic upside (tickers: SRPT long / IBB short) — Go long SRPT (1% NAV) and short IBB equal dollar (1% NAV) for 3–9 months to strip sector beta. Payoff: captures company-specific de-risking; risk if sector-wide rally outpaces idiosyncratic move.
• Volatility play around catalysts (ticker: SRPT) — Buy a calendar call spread (near-term short, longer-term long) sized to 0.5–1% NAV ahead of known readouts to exploit expected term-structure steepening. Target 1.5–2x return on premium within the next 3–6 months; stop if implied vol collapses >40% before catalysts.